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Abstract
A refined kainate (KA) C57BL/6J mouse model of status epilepticus (SE) using a repeated low dose (RLD) of KA (5 mg/kg,
intraperitoneal; at 30 min intervals) was compared with the established single high dose (SHD) of KA (20 mg/kg,
intraperitoneal) model. In the RLD group, increased duration of convulsive motor seizures (CMS, Racine scale stage$3) with
a significant reduction in mortality from 21% to 6% and decreased variability in seizure severity between animals/batches
were observed when compared to the SHD group. There was a significant increase in the percentage of animals that
reached stage-5 seizures (65% versus 96%) in the RLD group. Integrated real-time video-EEG analysis of both groups, using
NeuroScore software, revealed stage-specific spikes and power spectral density characteristics. When the seizures
progressed from non-convulsive seizures (NCS, stage 1–2) to CMS (stage 3–5), the delta power decreased which was
followed by an increase in gamma and beta power. A transient increase in alpha and sigma power marked the transition
from NCS to CMS with characteristic ‘high frequency trigger’ spikes on the EEG, which had no behavioral expression. During
SE the spike rate was higher in the RLD group than in the SHD group. Overall these results confirm that RLD of KA is a more
robust and consistent mouse model of SE than the SHD of KA mouse model.
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Introduction
Experimental animal models of seizures developed over many
decades, have undergone numerous modifications in an effort to
find the most appropriate preclinical model for screening
antiepileptic drugs (AEDs), and secondarily to reduce and refine
use of animals for in vivo experiments [1–8]. Despite the
development of numerous new AEDs and the introduction of a
variety of animal models of drug resistant epilepsy that supposedly
mirror the clinical condition, the percentage of epileptic patients
refractory to currently available AEDs still remains greater than
30% [9].
Rat models of seizure or epilepsy induced by chemoconvulsants
such as the glutamate analogue, kainate (KA) and the cholinergic
receptor agonist, pilocarpine have been commonly used for many
years. Rats produce fairly consistent status epilepticus (SE) [6,10,11]
with limited mortality rates (,15–20%) in most models [12–16].
However, over the past two decades, chemoconvulsant mouse
models of seizure and acquired epilepsy have begun to emerge
with the intention of utilizing transgenic mice in epilepsy research.
The most commonly used background strain of mouse for this
purpose is C57BL/6J [17–20]. C57BL/6J mice are known to
exhibit low sensitivity to chemoconvulsant induced seizures [21–
25].
Some studies have suggested that C57BL/6J mice show
inconsistent seizure response to the same dose of KA, given
systemically, even amongst animals derived from the same inbred
source or supplier [23,26–27]. Previous studies have demonstrated
that C57BL/6J inbred mice are genetically resistant to KA-
induced neurotoxicity and epileptogenesis [23,24,28–32]. The
genetic factor and unpredictable seizure threshold for KA between
batches of C57BL/6J mice might have contributed to increased
mortality rate due to severity of convulsive motor seizures (CMS)
during SE. From our preliminary experiments we found that in
some batches of mice there was a high mortality at 20 mg/kg,
while in the other batches high mortality was also observed at
10 mg/kg despite the source of KA and its formulation, and the
route of administration were being the same. To overcome these
disadvantages, we tested a repeated low dose (RLD) of KA in
C57BL/6J mice, titrated according to the development of epileptic
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behavior (5 mg/kg, i.p. at 30 min intervals), and compared this
with mice that received a single high dose (SHD) of KA (20 mg/
kg; i.p). In the present study, we demonstrate the advantages of
RLD over SHD model on mortality rate, behavioral seizures and
electrographic seizure quality during the SE. Further, using
integrated video-EEG NeuroScore software, we have identified
stage-specific spikes and power spectrum characteristics for each
stage of the behavioral seizure, and for the transition from non-
convulsive seizures (NCS) to CMS in both groups.
Materials and Methods
Animal source and ethics statement
Experiments were performed at two sites; University of
Liverpool (UoL), UK and Iowa State University (ISU), USA.
C57BL/6J male mice, 10–12 weeks old, were purchased from
Charles Rivers, UK or The Jackson Laboratory, ME, USA and
maintained in the Biomedical Services Unit at UoL or Laboratory
of Animal Resources at ISU. The mice were maintained under
controlled environmental conditions (19uC–23uC, 12 h light: 12 h
dark), with ad libitum access to food and water. All experiments
were carried out in strict accordance with the Animals (Scientific
Procedures) Act 1986 approved by the Secretary of State, Home
Office, UK (project license no. 40/3401) and Institutional Animal
Care and Use Committee, ISU, USA (protocol no. 10-12-7446-
MR). All surgeries were performed under isoflurane anesthesia
and all efforts were made to minimize discomfort and pain to
animals.
KA treatment and experimental groups
KA (Abcam, UK/USA) was prepared fresh in sterile distilled
water at a concentration of 2 mg/ml. Based on previous studies in
our laboratory [33], we considered a single dose of 20 mg/kg of
KA via intraperitoneal (i.p.) route to be a suitable method for
inducing CMS without very high levels of mortality. For RLD
method, a low dose of 5 mg/kg of KA per injection every 30 min
was given i.p. until the onset of Racine scale stage-5 seizures. The
behavior of all animals were video recorded throughout the
experimental period. Behavioral seizures were classified based on
modified Racine scale as: Stage-1, absence-like immobility; Stage-
2, hunching with facial or manual automatisms; Stage-3, rearing
with facial or manual automatisms and forelimb clonus; Stage-4,
repeated rearing with continuous forelimb clonus and falling; and
Stage-5, generalized tonic clonic convulsions with lateral recumb-
ence or jumping and wild running followed by generalized
convulsions. Seizure stages 1 and 2 were regarded as NCS while,
seizure stages 3 and higher were considered as CMS [34]. A
supplementary movie clip showing CMS stage-3 to -5 can be
found online (Video S1). Based on subtle behavioral and EEG
characteristics, we have subdivided the stage-3 into stage-3A and -
3B, which are described in the Results section.
One hundred and six mice were used for Racine scale scoring
behavioral experiments after KA injections. A total of 10 mice
died during SE; five out of 24 mice from the SHD group and 5 out
of 82 mice from the RLD group. Two hours after the first episode
of stage-5 seizure in RLD group or $ stage-3 seizure in SHD
group, the mice were treated with diazepam (10 mg/kg, i.m). All
mice were euthanized with an overdose of pentobarbital sodium
(100 mg/kg, i.p.) at the end of the experiments and the brain
tissues were archived.
Video-EEG recording
Eighteen mice were subcutaneously implanted with a telemetry
device (Physiotel and Multiplus ETA-F20, Data Science Interna-
tional, MN, USA) 8–10 days prior to KA treatment. Bilateral burr
holes were made, 2.5 mm caudal to Bregma and 2 mm lateral to
the midline, on each hemisphere and the electrodes were inserted
into the burr holes in contact with the dura mater. The burr holes
were closed by dental cement and the skin flaps were closed by
skin clips. The detailed surgical procedure for implanting the
electrodes and the transmitter has been described previously [33].
The RPC receiver pads, placed individually below each recording
cage, transmitted the EEG, movement activity and the body
temperature information via data exchange matrix to the
Windows PC. The real-time video and EEG recording was
captured simultaneously using DSI integrated video-EEG acqui-
sition software (DATAquest ART, DSI, USA). The EEG
recordings and the activity counts data obtained were analyzed
using NeuroScore (DSI) software.
Quantification of behavioral seizures
Video recordings from SHD and RLD groups were used to
score behavioral seizures on modified Racine scale at 5 min
epochs as previously described [33]. The persons scoring the
episodes were unaware of the treatment groups. In each epoch, the
highest seizure stage reached was considered. For example in a
5 min epoch, if stage-1 and -2 seizures occurred during the first
3 min followed by a 2 min stage-3 seizure, then the highest stage
considered for behavioral scoring was CMS stage-3. This way, the
seizure severity was calculated as cumulative seizure severity score
(mean 6 standard error) for the duration of SE based on the total
amount of time spent in CMS from the time they reached first
CMS to the time they received diazepam. The more severe the
seizures during the SE, the higher the score. In the present study
the SE refers to the 2 h duration starting from the first onset of
CMS (stage$3 for SHD group or stage-5 for RLD group) after
administering KA to the time-point they received diazepam.
Student’s unpaired t-test was used to compare the mortality rate,
duration of CMS and stage-5 seizures alone between the SHD and
RLD groups using GraphPad Prism software. To compare the
mortality rate between SHD and RLD groups, the mice that died
were taken as ‘‘0’’ and survived as ‘‘1’’. To compare the number of
animals that reached stage-5 seizures in SHD and RLD groups,
the mice that did not reach stage-5 was taken as ‘‘0’’ and the mice
that reached were taken as ‘‘1’’. The spike rate between SHD and
RLD groups were compared using two-way ANOVA.
Quantification of electrographic seizures
A minimum of 24 h baseline video-EEG was recorded for each
mouse before the KA treatment. The recordings were continued
to observe changes in EEG responses during KA administration.
All the post-KA responses were normalized against the baseline
from the same mouse. The artifacts in the raw EEG traces
(electrical noise, exploratory behavior and grooming) were
manually identified and excluded from the analyses. The EEG
spikes that corresponded to each behavioral Racine seizure stage
during a seizure, after KA administration, were regarded as
epileptiform spikes (Fig. 1). In order to differentiate epileptiform
spikes from the normal baseline spikes or from spikes due to
electrical or mechanical artifacts, we analyzed individual spike
characteristics such as amplitude, duration, frequency, inter-spike
intervals (Fig. 1) and the activity counts (per min) during this
period. In the EEG recordings, the epileptiform spike character-
istics for each seizure stage was compared between SHD and RLD
groups. The activity monitor module in the implanted telemetry
device in the mouse detected the areas of high activity such as
exploratory movements, grooming and seizures. Based on these,
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the activity threshold for CMS was set at 0.1 Hz and the activity
was recorded as counts/min.
The raw EEG signal was divided into 10 s epochs, after
manually excluding artifacts, and subjected to Fast Fourier
Transform (FFT) to generate power bands. The signal component
consisting of various frequencies were split into individual power
bands corresponding to delta (d, 0.5–4 Hz), theta (h, 4–8 Hz),
alpha (a, 8–12 Hz), sigma (S, 12–16 Hz), beta (b, 16–24 Hz) and
gamma (c, 24–80 Hz) [35,36,37]. The power in different spectra
altered depending on the stage of a seizure episode and the power
in some bands increased as the seizure progressed from stage-1 to -
5. The mean 6 standard error values pooled from 10 s epochs for
parameters such as spike counts, amplitude and power band (mV2)
were compared between SHD and RLD groups using Student’s
unpaired t-tests.
Results
RLD of KA reduces mortality rate and increases the
number of animals that reach stage-5 seizures when
compared with SHD
All animals that received KA either as a SHD or as a RLD
showed behavioral and electrographic seizures. The severity of
seizures was classified according to the modified Racine scale [38]
ranging from stage 1–5 that was previously described for C57BL/
6J mouse in our publication [33]. In the present study, for RLD
group, the first onset of stage-5 seizure was considered as the
starting point of SE since 96% of mice reached stage-5 seizure
(Fig. 2). For SHD group, the first onset of CMS-3 was considered
as the starting point of SE since only 65% reached stage-5 seizure,
however 91% of mice reached stage-3 (Fig. 2). In both groups, SE
was terminated 2 h later which was considered as the end point of
SE.
RLD of KA when given as 5 mg/kg at 30 min intervals resulted
in a significant lower mortality rate (6% versus 21%; p= 0.029,
unpaired t-test) than in a SHD of KA (20 mg/kg) (Fig 2A–B). This
is despite the RLD group often receiving up to 35 mg/kg more
KA than the SHD group. Importantly, there was a significant
increase in the percentage of animals that reached stage-5 seizures
in the RLD group when compared to the SHD group (96% versus
65%; p= 0.001, unpaired t-test; Fig 2C–D). In the RLD group,
76% of the animals reached stage-5 seizures with #25 mg/kg and
the rest between 30 and 55 mg/kg of KA (Fig 3A). The majority of
RLD group animals remained at stage $3 more frequently once
they reached stage-5 (Fig. 3B–D) while in the SHD group it varied
from stage-1 to stage-5 (Fig. 3E). A supplementary movie clip
showing CMS stage-3 to -5 can be found online (Video S1). The
RLD group of animals that received the same amount of KA as
SHD group (20 mg/kg) spent twice the total amount of time at
stage $3 (p,0.0001, unpaired t-test) or stage-5 alone (p = 0.049,
unpaired t-test) during the SE than the SHD group (Fig. 4A–C).
Interestingly, in the RLD group there was no correlation between
the total dose of KA received and seizure severity or the earliest
time-point at which stage-5 was reached (Fig. 3C–D). Overall,
RLD of KA regimen reduced wastage of animals by 46% i.e., 15%
due to difference in mortality rate and 31% due to those that did
not reach stage-5 seizures in SHD group.
From quantitative perspective, in the present study, SE is
quantitatively defined as the ‘total amount of time spent in CMS
$3’ once they reach first CMS- 5 (RLD) or CMS-3 (SHD) to the
time-point when diazepam was administered (which is typically
calculated from 2 h duration of SE). This is represented as
cumulative seizure severity score in figure 3B for individual mouse
Figure 1. Individual spike characteristics on EEG. The baseline non-epileptiform spike and artifact spikes are shown in the top panel (A). The
bottom panel (B) represents epileptiform spikes at different stages of seizures. Baseline spike, stage-1 and stage-2 epileptiform spikes are simple
while, high frequency trigger (HFT), stage-3, -4 and -5 were complex. Stage-1 epileptiform spikes were similar to baseline spikes but had higher
amplitude. Stage-2 epileptiform spikes had higher amplitude than stage-1. As stage-2 progressed towards CMS the spikes became complex with mini
HFT-like spikes (indicated by the arrow). Several small spikes at the peak of the stage-4 spike gave a characteristic appearance of a paint brush. Stage-
5 epileptiform spikes had a low amplitude when compared to the stage-4 spikes but had a combination of stage-2 to-4 spikes. Scale for all: y-axis
300 mV and x-axis 300 ms.
doi:10.1371/journal.pone.0096622.g001
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in RLD group that received various amounts of KA to achieve SE.
We have also compared the quantitative SE i.e., the total amount
of time spent in CMS $3 during the 2 h SE, between the SHD
and RLD groups that received the same amount of KA (20 mg/
kg). This is represented for individual mouse in figure 4A and for
the groups in figure 4B.
Individual spike characteristics, spiking rate and EEG
signature for different stages of behavioral seizures in
RLD and SHD group
We detected stage-specific epileptiform spiking characteristics
from the EEG traces for different stages of behavioral seizures
during the SE, which were confirmed by real-time video
recordings using the NeuroScore software (Fig. 5). The epilepti-
form spikes were differentiated from artifact spikes based on
amplitude, duration, interspike interval and spike rate (spike
frequency per minute) (Fig. 1, Fig. 6; Table 1). Power spectrum
characteristics and activity counts for each seizure stage were also
identified (Fig. 5; Table 1).
The artifact spike due to electrical interference had an
amplitude of more than 2 mV with the duration of ,20 ms for
each spike. These spikes were observed on EEG as occasional
spikes or in clusters, and produced no activity counts. However,
when these spikes occurred as a cluster, it increased all power
bands within the 10 s epoch, with the power ranging from 200 to
2000 mV2. Such artifacts were identified and excluded from the
analysis. Spikes due to mechanical movement such as exploratory
behavior showed a slow spike as shown in Figure 1 with activity
counts up to 80/min with no change in the power spectrum. EEG
for grooming was characterized by a slow amplitude spike
containing series of oscillating spikes with no change in activity
counts, however, increased delta (up to 700 mV2), theta (up to
100 mV2) and alpha (up to 10 mV2) power bands in 10 s epochs.
The other power bands were unaffected by grooming behavior.
A baseline spike is a non-epileptiform spike with a low
amplitude ,200 mV and with no change in the power spectrum.
Baseline spikes and, stage-1 and stage-2 epileptiform spikes were
simple spikes while, high frequency trigger (HFT) and, stage-3, -4
and -5 were complex spikes (Fig.1, Fig. 5). Stage-2 epileptiform
spikes had higher amplitude than stage-1. As stage-2 progressed
towards CMS, the spikes became complex with mini HFT-like
spikes (indicated by an arrow in Fig. 1). These mini-HFT spikes
later became isolated and represented as high frequency clusters
on EEG which marked the transition from stage-2 to -3A (Fig.5).
Several small spikes at the peak of the stage-4 epileptiform spike
gave a characteristic appearance of a ‘paint brush’ (Fig.1). Stage-5
epileptiform spikes had a low amplitude when compared to the
stage-2 to -4 spikes (Fig.1). The details of stage-1 to -5 epileptiform
spikes characteristics are given in Table 1. There were no
differences with respect to stage-specific spike characteristics
between SHD and RLD groups.
As previously described, NCS included stage-1 and -2 seizures.
Stage-1 behavioral seizure was represented on EEG as stage-1
epileptiform spikes. The stage-2 epileptiform spikes resembled the
periodic epileptiform discharges (PEDS) in both SHD and RLD
groups that were similar to the pattern number 2 that we had
described previously [33]. We have identified a third pattern of
epileptiform spikes, HFT, on the EEG trace which preceded the
CMS (Fig. 5) in both RLD and SHD groups. Interestingly, this
short HFT period had no behavioral seizure characteristics. The
HFT spikes had an amplitude of 300–1000 mV with a short
duration of 20–40 ms. They had an inter-spike interval of 25–
60 ms with a frequency of 120–200spikes/min (Fig. 5; Table 1).
We introduce a subclass under CMS stage-3 based on subtle
behavioral changes, which were correlated with EEG character-
istics during the SE. This is a further modification to our
previously described modified Racine scale for behavioral seizures
[33]. Stage-3A was characterized by rearing with facial/manual
automatism but no forelimb clonus. Stage-3B represented rearing
continuous with facial/manual automatism and continuous
forelimb clonus (piano playing-like posture) with Straub tail. The
epileptiform spikes characteristics for stage-3A and -3B are given
in Table 1 and Figure1 and 5. The stage-4 behavioral seizure
showed repeated rearing with continuous forelimb clonus and
frequent falling which corresponded to the spikes on the EEG that
had an amplitude of 400 to 700 mV with a spike duration of 200–
300 ms. There were no obvious differences in stage-3A, -3B and -4
spiking rate and amplitude between the SHD and RLD groups
(Fig. 6A, 6C). Stage-5 seizures were manifested by generalized
tonic clonic convulsions with lateral recumbence or jumping and
wild running followed by generalized convulsions. The stage-5
spike clusters contained a combination of stage-2 to -4 spikes
(Fig. 1B). When the mice showed jumping behavior during stage-5
seizure, there was a corresponding ‘‘baseline shoot’’ for .1.5 s on
EEG (Fig. 5C). As the stage-5 seizure progressed, the rigidity
corresponded to a low amplitude spikes that were smaller than the
baseline on the EEG (Fig.5C). The mortality during SE in the
SHD group was more frequently preceded by recumbent and
Figure 2. The effects of RLD and SHD of KA on mortality rate
and severity of behavioral SE. RLD of KA ranging from 15–55 mg/
kg (3–11 doses of 5 mg/kg at 30 min intervals, i.p.,) reduced mortality
rate (A, B) and increased the percentage of animals that reached stage-5
seizures. The RLD method reduced inter-animal variability during
different stages of SE (C, D). The lower case letters in pie charts A and B
indicate mortality (a) during the SE, (b) soon after diazepam or (c) soon
after KA injection (,10 min). The numbers in pie charts C and D
indicate the stages of the seizures. N = 82 for RLD group; five mice died
during SE after reaching stage-5 seizures, three mice did not reach
stage-5 seizure, all mice except one reached stage-3 seizures; N = 24 for
SHD group, five mice died during SE after reaching stage-5 seizures,
eight mice did not reach stage-5, and 2 mice did not reach stage-3.
p = 0.029 for mortality and p= 0.001 for SE.
doi:10.1371/journal.pone.0096622.g002
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Figure 3. SE response over time to various doses of KA given at 5 mg/kg at 30 min intervals and to a single dose of 20 mg/kg. A: A
total of 82 mice were used for RLD of KA. About 95% of the animals reached stage-5 seizures with #35 mg/kg. B: Cumulative Seizure severity score
for the 2 h duration of SE between the first stage-5 (RLD) seizure and diazepam administration. Irrespective of the total dose of KA, the vast majority
of animals stayed at stage$3 seizures after the first stage-5 seizure. Each marker represents a mouse that had achieved SE at a given RLD of KA. C–D:
Represent SE response to RLD of KA over time for an individual mouse (circled and indicated by C and D in Fig. 3B). There was no correlation between
the total dose of KA received and seizure severity or the earliest time-point at which animals reached stage-5 seizures. E: SE response of mouse to a
SHD of KA at 20 mg/kg over time. This mouse had a fewer CMS during the 2 h period of SE after the onset of the first stage-5 seizure.
doi:10.1371/journal.pone.0096622.g003
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generalized rigidity during stage-5 seizures. However, in the RLD
group the vast majority of the mice recovered from this behavior.
RLD group showed higher spike rate than the SHD group
during the SE
Overall, the spike rate (spikes/min) was greater in the RLD
group than in the SHD group in all stages of seizures. The stage-2
and stage-5 epileptiform spike rates were significantly higher in the
RLD group than in the SHD group (Fig. 6A; p = 0.021 for stage-2,
p = 0.0012 for stage-5). Total spike counts in 5 min epochs (as
spike/min) throughout the SE were also significantly increased in
the RLD group (Fig. 6B, n = 9 each group, p,0.0001, F= 107.6,
two way ANOVA with 1 and 384 degrees of freedom). In stage-5,
there was also a significant increase in amplitude (p = 0.024) in the
RLD group when compared with the SHD group (Fig. 6C).
In the present study, the quantitative SE for SHD mice had an
average duration of behavioral CMS $3 for $25 min (Fig. 4B)
with an average spike rate of$252/min, while RLD group had an
average duration of behavioral CMS $3 for $60 min (Fig. 4B)
with an average spike rate of $346/min. The average spike rates
for SHD and RLD groups were calculated by pooling the number
of stage-specific spikes/min during stage-3A to -5 as shown in
figure 5 and 6A.
The power bands characteristics on EEG for different
stages of behavioral seizures
We determined power band spectrum for frequencies ranging
from 0.5 to 80 Hz based on stage-specific EEG characteristics and
the corresponding increased activity counts in 10 s epochs. The
power band spectrum consisted of d, h, a, S, b and c frequencies
across different stages of seizures (Fig. 5, Table 1). As the seizure
stages progressed from stage-1 to -5, the EEG patterns with
increase in power bands began to emerge (Fig. 5). A magnified
2 min trace of a seizure episode shows stage-specific spike
characteristics (amplitude, duration and inter-spike intervals). A
corresponding power bands at 10 s epochs above the EEG trace
and activity counts below the EEG trace across different stages of
seizures are also shown (Fig. 5).
It is important to note that when seizures progressed from NCS
to CMS, there was a visible increase in power in different bands in
the EEG trace, especially power in the gamma band (Fig. 5). The
gamma power increased after HFT, reached its peak during stage-
3B and declined in stage-4 and -5 before reaching the baseline
(Fig. 5). Higher delta and theta power was the hallmark of stage-2
spikes (PEDS). A reduction of peaked delta power and an increase
in beta and gamma power marked the progression from NCS to
CMS. The HFT pattern marked this transition which was
characterized by a brief peak in alpha and sigma power. A
transient increase in theta power marked the transition between
stage-3A and -3B. Both beta and gamma power peaked in stage-
3B and declined marginally in stage-4 and -5 before reaching the
baseline (Fig. 5). There were no significant differences between the
SHD and RLD groups in terms of power bands at different stages
of seizures during SE (Fig. 7).
Activity counts (per min) increased from stage-3A and peaked in
stage-3B and stage-4 (Fig. 5). Activity counts reduced in stage-5
when the mice were recumbent or during generalized rigidity, but
increased when the mice showed jumping behavior during stage-5
seizures.
Discussion
We have demonstrated the advantages of a RLD of KA to
induce SE in C57B/6J mice, titrated according to the develop-
ment of epileptic behavior and terminating SE with diazepam 2 h
after the first expression of stage-5 seizures. We assessed this
method, and compared it with conventional SHD method, by
quantifying behavioral and electrographic indicators of SE severity
as described previously [33]. RLD method could reliably induce
SE with a prolonged period of repeated stage $3 seizures which
was confirmed by an increased frequency of epileptiform spiking
during the SE when compared to the SHD group. We have also
identified stage-specific epileptiform spikes and power spectrum
characteristics in EEG which were validated by integrated real-
time video-EEG recordings and activity counts. A RLD of KA
reduced the mortality rate from 21% to 6% when compared with
the SHD and the percentage of animals that reached stage-5
seizures was increased from 65% in the SHD group to 96% in the
RLD group. C57BL/6J mice have previously been reported as
Figure 4. Seizure severity (total amount of time spent in CMS)
comparison between SHD and RLD at 20 mg/kg (total dose in
RLD or a single dose in SHD group). A–C: Suggests that the RLD
method produces consistently severe seizures when compared to SHD.
Each point on graph A represents an individual mouse at a specific CMS
stage. B: Histogram comparing the mean 6 standard error of seizure
severity in SHD and RLD groups (both groups received a total of 20 mg/
kg KA) based on the total amount of time spent in CMS during the 2 h
SE period from the time the mice showed first CMS-3 (SHD) or CMS-5
(RLD) to the time they received diazepam C: Comparison of the amount
of time spent in stage-5 alone between the two groups revealed that
the RLD group had more stage-5 seizures than the SHD group (n = 19
for SHD; n = 33 for RLD; *p = 0.049, *** p,0.0001).
doi:10.1371/journal.pone.0096622.g004
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being less sensitive to chemoconvulsants [21–25] and vary in
mortality rate between mice obtained from different sources [39].
Our results from RLD of KA, when compared to the SHD
method, in C57BL/6J mouse model reduces variability between
batches/sources and produces a robust and consistent mouse
model of SE.
C57BL/6J mice are more resistant to the acute effects of KA-
induced toxicity, given systemically, when compared to other
inbred strains and show varied seizure responses to the same dose
of KA [2,23,27,28,40,41]. This variability might contribute to an
unpredicted mortality rate. This is one of the major concerns for
researchers who use C57BL/6J mouse as an acute seizure model
in epilepsy research. Moreover, the majority of transgenic mice are
developed on this genetic background [18,42] and therefore it is
becoming an increasingly important area of research to develop an
appropriate C57BL/6J mouse model [2,3,43,44] or to refine the
existing models, which has been done in rats [10,16,45,46]. Very
recently, Loscher group in Germany have reported a C57BL/6
substrain of mouse which is significantly more susceptible to SE
induction than any other C57BL/6 substrain [3] including the
strain that we have been using for some time, C57BL/6J [33].
When compared to conventional SHD of KA, RLD method
afforded the ability to maximize the severity and duration of SE,
whilst simultaneously limiting variability and associated mortality
as seen in other models [46,47]. This is particularly important in
highly invasive procedures that are expensive in cost and time,
such as implanting of electrodes for recording EEG. Similar
approaches have previously been used in rats to induce SE
[10,46,47]. By administering KA by RLD method, titrated
according to behavior, we demonstrate that a highly consistent
period of SE with a prolonged period of repeated stage $3
seizures can be achieved in C57BL/6J mice. These findings, with
respect to severity and duration of SE, are similar to those reported
using a RLD of KA in rats by other groups [10,34,46]. These
Figure 5. An example of an EEG trace (for 2 min) showing different stages of seizure episodes, induced by KA in C57BL/6J mouse,
correlating with power spectrum, activity level and real-time behavioral seizures captured from video-EEG recording. A: EEG trace in
the middle shows changes in the electrical activity as the seizure severity progressed from NCS to CMS over time. A brief HFT on the EEG, which had
no behavioral counterpart, preceded the CMS. Different stages of behavioral seizures are shown by photographs (C). Magnified 2 second traces (B)
representing EEG signatures for each stage of behavioral seizure. The histograms at the top panel in ‘A’ represent power bands. The baseline power
of all bands was less than 5 mV2 and the amplitude of the baseline was ,200 mV. As the seizure progressed from NCS to CMS, the power bands, and
especially gamma power, increased (shown in green). Gamma power band increased after HFT, peaked at stage-3B, and started declining in stage-4
and -5 before returning to the baseline. Activity counts (per min), shown below the EEG trace, increased from stage-3A onwards and peaked in stage-
3B and -4. Activity counts reduced in stage-5 when the mice were recumbent or showed generalized rigidity but, increased when the mice displayed
jumping behavior. A higher delta band was found to be the hallmark of stage-2 seizures. Reduction in the peaked delta band was characteristic when
NCS progressed to CMS. HFT was characterized by a peak of alpha and sigma bands. A transient increase in theta band marked the transition from
stage-3A to -3B. Gamma and beta bands peaked in stage-3B and declined slowly in stage-4 and -5 before reaching the baseline.
doi:10.1371/journal.pone.0096622.g005
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research groups administered KA systemically at a dose of 5 mg/
kg per hour until animals showed class IV-V (equivalent to stage-
4/5 in the present study). Glien et al [47] also found similar results
with a RLD induction method using pilocarpine. Repeated KA
dosing protocols have also been reported in C57BL/6J mice by
other groups. McKhann et al [28] gave subcutaneous injections of
6–12 mg/kg of KA for every 60–90 min until CMS were
observed. In another study, Yang et al [27] used 5 mg/kg KA
in C57BL/6J mice, also subcutaneous, but at 1 h intervals. In
these studies, an increase in severity and inter-individual
uniformity was also reported, however, they have not been
directly compared with animals receiving a single dose, and the
characterization of the development of electrographic SE and
power spectrum analyses was not done. Moreover, the first dose of
KA was typically high in McKhann et al study, the interval
between injections was longer due to subcutaneous route, and the
mortality rate was 57% (C57BL/6J mice) in those studies [28].
This high mortality rate could be due to prolonged SE or due to
the fact that SE was not terminated pharmacologically. With
respect to the effect of the prolonged duration of SE, our
behavioral findings are in close agreement with Yang et al. [27]
whose treatment regimen was similar to the present study
Figure 6. The RLD group had a higher spike count (per min) than the SHD group. Spike counts were higher across all stages of seizures (A)
or in the total spike count during the entire 2 h duration of SE following RLD (B). The increase in spike counts was significantly greater during stage-2
(p = 0.021) and stage-5 (p = 0.0012) seizures in the RLD group than in the SHD group (A). The mean values of spike rate shown at 5 min epochs
revealed a significant increase in the RLD group than in the SHD group (two way ANOVA, p= 0.0001, n = 9 each). C: The spike amplitude during the
2 h SE was greater in stage-3B $ stage-2 . stage-3A $ stage-4 $ stage-5 . stage-1. There was a significant increase in spike amplitude for stage-5
seizures in the RLD group (p = 0.024, n = 9 each, unpaired t-test).
doi:10.1371/journal.pone.0096622.g006
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including SE termination (albeit using pentobarbitone rather than
diazepam and a different route of administration of KA). However
by comparison, our method yielded much lower mortality rate i.e.,
6% as opposed to 27% and 57% in other studies [27,28]. In our
study, in addition to recording behavioral SE, we have also
quantified electrographic seizures, validated them in relation to
real-time video recordings of behavioral SE and made direct
comparisons between those induced by RLD and SHD of KA. It is
interesting to note that in RLD group, the stage-2 spikes (PEDS-
like spikes) and stage-5 spike frequency was higher than in the
SHD group. These findings also validate RLD as the most robust
method of SE. PEDS pattern is emerging as a candidate for
predictor of EEG seizures [53]. Staley et al [54] proposed that the
correlation of spikes and epilepsy has long been recognized and
forms the basis for the diagnostic use of the EEG. The spike
characteristics identified in the present study may support the
prognostic significance of spikes and their frequency in experi-
mental models of epilepsy and this approach has been utilized in
human temporal lobe epilepsy and epilepsy-related surgeries [55–
58]. In the present study, in addition to PEDS-like spikes we have
also identified ‘‘HFT’’ spike pattern with no behavioral correlates,
which marked the transition between NCS to CMS. Although at
present there is no evidence from the literature to support this
finding, like PEDS, HFT pattern may be useful as a predictor of
CMS.
It has been reported that C57BL/6J mice are more resistant to
KA-induced excitotoxic cell death when KA was administered
intraperitoneally at a dose ,30 mg/kg [23,27,28]. High doses of
KA (.30 mg/kg) required to induce CMS caused death of CA1
pyramidal cells in C57BL/6J mice [23]. Benkovic et al [30] have
also demonstrated widespread neurotoxicity following KA treat-
ment (35 mg/kg) in C57BL/6J adult mice. KA administration
disrupts blood-brain-barrier irrespective of the dose of KA used
[27,30,48]. Recent evidence suggests that intra-hippocampal [59–
61] or intranasal administration [62–63] of KA causes localized
neuron death in the hippocampus. Interestingly, there are no
strain differences (KA-susceptible DBA and KA-resistant C57BL/
6J) in the basal level of expression of KA or AMPA receptors in
hippocampus and other brain regions [26,49]. This means that
irrespective of the amount of KA administered in RLD group, the
receptor density is unchanged and the overall effects of KA are
due to summation of all receptor activities. It is speculative at this
stage that, as the brain concentration of KA increases, following
either SHD or RLD, it could activate NMDARs in addition to KA
and AMPA receptors in the hippocampus [50,54]. Experimental
evidence suggests that the activation of these receptors in the
hippocampal network and the entorhinal cortex generate post-
synaptic potentials [51,52]. According to Lehmkuhle et al [35], the
power in the gamma band reflects the frequency range of
excitatory postsynaptic potentials that would be expected to occur
during seizures. In the present study, the dynamic gamma and
beta power were observed in the EEG during CMS in both SHD
and RLD groups. There were no statistically significant differences
in any of the power spectral bands at any stages between SHD and
RLD. One plausible reason is that in RLD group there were more
number of stage-5 seizures which were not always associated with
increased beta and gamma power in 10 s epochs and the
maximum power was evident only during the stage-3B (Fig. 5),
which was similar in both SHD and RLD groups. We observed
higher delta and theta frequencies in stage-2 (NCS) spiking which
were similar to ‘absence seizure’ rat model (WAG/RiJ) [64–65].
During the transition from NCS to CMS, an increase in alpha and
sigma bands were observed in HFT spiking pattern in the present





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Repeated Low Dose of Kainate in C57BL/6J Mouse
PLOS ONE | www.plosone.org 9 May 2014 | Volume 9 | Issue 5 | e96622
determined in predicting spontaneous recurrent seizures in
chronic epilepsy model.
In summary, RLD of KA in C57BL/6J mice decreases SE
variability, reduces mortality rate and produces consistent
prolonged CMS and electrographic SE when compared to the
SHD of KA. Integrated video-EEG data analysis provides stage-
specific spike and power spectrum characteristics that occur during
SE and has great potential for facilitating screening of pharma-
cological interventions targeting NCS and CMS. Application of
these parameters in our ongoing post-SE studies in both mouse
and rat models of epilepsy provide a valuable means of identifying
genuine spontaneous recurrent seizures and inter-ictal spikes.
Because the C57BL/6J is the most popular background strain for
genetic manipulations, the development of a more useful model of
chronic epilepsy, beyond SE, would be a major step forward.
Supporting Information
Video S1 A movie demonstrating convulsive motor
seizures stage-3 to -5 (Racine 3–5) in C57BL/6J mouse.
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